MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Erasca Inc

Cerrado

2.43 -2.8

Resumen

Variación precio

24h

Actual

Mínimo

2.4

Máximo

2.74

Métricas clave

By Trading Economics

Ingresos

-2.9M

-34M

Margen de beneficios

-768.16

Empleados

103

EBITDA

-2.5M

-38M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+39.48% upside

Dividendos

By Dow Jones

Próximas Ganancias

10 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

242M

661M

Apertura anterior

5.23

Cierre anterior

2.43

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2025, 16:58 UTC

Ganancias

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct 2025, 23:19 UTC

Charlas de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct 2025, 22:40 UTC

Charlas de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 20:44 UTC

Acciones populares

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct 2025, 19:42 UTC

Charlas de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct 2025, 19:23 UTC

Adquisiciones, fusiones, absorciones

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct 2025, 15:33 UTC

Charlas de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct 2025, 15:25 UTC

Charlas de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct 2025, 15:15 UTC

Charlas de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct 2025, 15:04 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 oct 2025, 15:04 UTC

Charlas de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct 2025, 14:52 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

39.48% repunte

Estimación a 12 Meses

Media 3.25 USD  39.48%

Máximo 6 USD

Mínimo 1 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

2

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Very Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat